By comparing these therapeutic approaches, this study seeks to elucidate whether SGLT2 inhibitors offer a multifaceted advantage in managing T2DM and CKD, potentially reducing therapeutic inertia and easing polypharmacy by addressing multiple risk factors with a single agent. This evidence concerns the gene SLC5A2 and chronic kidney disease.